Evidence map›Paper›PMID 41827821›Full record

ArticleCells2026

Human FGF1

Yingjian Li, Xiaodan Hui, Chunjie Gu, Qian Lin, Ahmed Abdelbaset-Ismail, Zixuan Xu, Suchen Yadav, Hongbiao Huang, Jason Xu, Sara E Watson and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yingjian LiPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Xiaodan HuiPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Chunjie GuPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Qian LinTouchstone Diabetes Center, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.ORCID 0000-0002-6712-7431
Ahmed Abdelbaset-IsmailPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Zixuan XuPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Suchen YadavPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-0517-9527
Hongbiao HuangPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Jason XuPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Sara E WatsonWendy Novak Diabetes Institute, Norton Children's Hospital, Louisville, KY 40202, USA.
Kupper A WintergerstWendy Novak Diabetes Institute, Norton Children's Hospital, Louisville, KY 40202, USA.ORCID 0000-0002-8373-061X
Lu CaiPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0003-3048-1135
Zhongbin DengDivision of Immunotherapy, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Yi TanPediatric Research Institute, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.

Funding

Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosisR01HL160927 · NHLBI · UNIVERSITY OF LOUISVILLE · 2022 to 2025
$2.2M
Dual targeting chemokine receptors prevents chemotherapy-induced cardiotoxicityR01HL174922 · UNIVERSITY OF LOUISVILLE · 2025 to 2025
$682k
NHLBI NIH HHS R01 HL125877NHLBI NIH HHS R01 HL160927NHLBI NIH HHS R01 HL174922NIH Common Fund R01HL125877, R01HL160927, R01HL174922, R01DK131442, R01DK115406, and P30ES030328
6 · The paper itself

Abstract

The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising worldwide. hFGF1

Indexed as

Apolipoproteins EFatty LiverFibroblast Growth Factor 1Genetic TherapyAnimalsDependovirusGene Therapy AgentsHumansLiverMaleMiceMice, Inbred C57BLMice, Knockout, ApoEApolipoproteins EFibroblast Growth Factor 1AAV8 gene therapyhFGF1ΔHBSMASHsystemic metabolism

Identifiers

PMID41827821
PMCPMC12984195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.